Category: Coartem

  • Novartis drug raises hope of tackling malaria drug resistance

    More than two decades ago , Novartis made a big contribution to the fight against malaria when it won approval for Coartem, the first artemisinin-based combination therapy (ACT), which has transformed care for people with the parasitic infection. Now – over a billion doses of Coartem (artemether-lumefantrine) later – the drugmaker thinks it may have […]